# Research timeline and gaps: CCSVI and Liberation Therapy for Multiple Sclerosis

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2009 — Foundational case-control association proposes MS-specific venous abnormalities; PubMed issue year2009 follows online2008.** [Original PMID19060024](https://pubmed.ncbi.nlm.nih.gov/19060024/).

**2009 — Open-label venoplasty reports pressure and selected RRMS changes, with high jugular restenosis.** [Original PMID19958985](https://pubmed.ncbi.nlm.nih.gov/19958985/).

**2011 — Objective balloon-only jugular thrombosis documents a possible procedural complication.** [Original PMID21803799](https://pubmed.ncbi.nlm.nih.gov/21803799/).

**2014 — Blinded sibling/control venography challenges disease-specific pathological narrowing; issue2014 follows online2013.** [Original PMID24119384](https://pubmed.ncbi.nlm.nih.gov/24119384/).

**2014 — PREMiSe randomized pilot tests sham comparison and target engagement without demonstrated clinical efficacy.** [Original PMID24975855](https://pubmed.ncbi.nlm.nih.gov/24975855/).

**2018 — Brave Dreams finds no clinical functional benefit with incomplete flow correction; online2017, issue2018.** [Original PMID29150995](https://pubmed.ncbi.nlm.nih.gov/29150995/).

**2018 — Independent Canadian sham trial finds no primary QOL or secondary clinical/MRI benefit.** [Original PMID30266886](https://pubmed.ncbi.nlm.nih.gov/30266886/).

**2020 — Expanded same-trial MRI analysis provides a positive lesion-free lead; online2019, issue2020.** [Original PMID31735108](https://pubmed.ncbi.nlm.nih.gov/31735108/).

## Research gaps

Validate a stable pathological-obstruction definition using independent blinded acquisition, pressure/flow and sibling/healthy controls.

Separate procedural success, sustained target engagement and clinical mediation; low engagement is a limitation rather than a responder-defined rescue.

Prospectively test the favorable-anatomy MRI lead against clinical outcomes and multiplicity control in an independent cohort.

Clarify stage, collateral and inflammatory mechanisms without generalizing rat iron/gliosis to human demyelination.

Establish objective long-term complication denominators by balloon/stent and operator setting with independent causal adjudication.

Audit supplements and correction bodies unavailable in this bounded source examination; do not convert access failures to negative findings.

## Boundary experiment

If a scientifically and ethically justified study is contemplated, prospectively fix anatomical/pressure entry criteria and MS stage, verify sustained flow correction, randomize balloon venoplasty versus convincing sham with stable usual therapy and adequate clinical power, and test prespecified functional/relapse outcomes alongside MRI without conditioning on post-treatment responders.